Diana Osorio, MD, MPH, reviews a case of a pediatric patient with an unresectable cervicomedullary ganglioglioma harboring a BRAF V600E mutation, highlighting the role of molecular testing in identifying an actionable alteration and guiding BRAF/MEK-targeted therapy.
Nathan Robison, MD, presents a case of a 14-year-old male with a progressive hypothalamic low-grade glioma whose newly identified KIAA1549::BRAF fusion informs consideration of next-line treatment options after years of relative stability.
Matthew Cascio, DO, reviews second-line treatment for a case of BRAF V600E-mutated recurrent or refractory pediatric low-grade glioma, following initial combination treatment with dabrafenib and trametinib.
Sameer Farouk Sait, MBBS, reviews a case of focal BRAF fusion–positive pediatric low-grade brainstem glioma that initially responded to chemotherapy but later recurred, prompting molecularly guided targeted therapy complicated by treatment-related toxicities.
Nicholas Whipple, MD, MPH, reviews a case of extensive pediatric optic pathway glioma with progression on chemotherapy and MEK inhibition, highlighting the role of molecular testing, BRAF/MEK-targeted therapy, and considerations for treatment selection at recurrence.
Mohamed Shebl Abdelbaki, MD, presents a case of a 9-year-old girl with unresectable BRAF V600E–mutant thalamic pilocytic astrocytoma who experienced severe pyrexia and treatment intolerance on dabrafenib plus trametinib, prompting consideration of alternative therapeutic options.
Matthew Cascio, DO, presents a case of a 3-month-old infant with a bilateral optic pathway glioma that progressed on frontline carboplatin and was subsequently found to be a BRAF V600E–mutated pilocytic astrocytoma.
Lindsey Hoffman, DO, presents a case of a 10-year-old girl with an unresectable BRAF V600E–mutated brainstem ganglioglioma causing obstructive hydrocephalus and visual symptoms, highlighting treatment considerations when further surgical resection is not feasible.
Ashley Margol, MD, MS, presents a case of a 7-year-old girl with a KIAA1549-BRAF fusion–positive pilocytic astrocytoma that remained stable during and after carboplatin-vincristine therapy before progressing nearly 2 years later with new neurologic symptoms requiring additional treatment.
Mohamed Shebl Abdelbaki, MD, presents a case of a 1-year-old boy with a KIAA1549-BRAF fusion–positive brainstem ganglioglioma that demonstrated significant radiographic progression after 3 months of carboplatin and vincristine therapy, prompting consideration of alternative treatment strategies.
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Based on results from the LITESPARK-011 trial, the FDA has approved belzutifan plus lenvatinib following PD-1 or PD-L1 inhibitor therapy for patients with advanced clear cell renal cell carcinoma, providing a new combination treatment option...
Updated results from the phase 3 ECHO trial demonstrated that adding acalabrutinib to bendamustine and rituximab prolonged progression-free survival and delayed subsequent treatment in older patients with treatment-naïve mantle cell lymphoma,...
Updated results from the phase 3 ECHO trial demonstrated that adding acalabrutinib to bendamustine and rituximab prolonged progression-free survival and delayed subsequent treatment in older patients with treatment-naïve mantle cell lymphoma,...
Results from the ARROS-1 trial demonstrated that zidesamtinib produced high and durable systemic and intracranial response in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer, supporting continued investigation of the...
Results from the ARROS-1 trial demonstrated that zidesamtinib produced high and durable systemic and intracranial response in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer, supporting continued investigation of the...
An FDA advisory committee voted in favor of GRAIL’s Galleri multi-cancer early detection test for adults aged 50 years and older, supporting its safety, effectiveness, and overall benefit-risk profile as the agency continues review of its...
An FDA advisory committee voted in favor of GRAIL’s Galleri multi-cancer early detection test for adults aged 50 years and older, supporting its safety, effectiveness, and overall benefit-risk profile as the agency continues review of its...
Based on results from the REFOCUS trial, the FDA has approved lirafugratinib for previously treated patients with unresectable or advanced FGFR2-altered cholangiocarcinoma, providing an additional targeted treatment option for patients with...
Based on results from the REFOCUS trial, the FDA has approved lirafugratinib for previously treated patients with unresectable or advanced FGFR2-altered cholangiocarcinoma, providing an additional targeted treatment option for patients with...
The FDA approved Bravnetsa for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors, introducing a bioequivalent and therapeutically equivalent lutetium Lu 177 dotatate radioligand therapy through the abbreviated new drug...
The FDA approved Bravnetsa for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors, introducing a bioequivalent and therapeutically equivalent lutetium Lu 177 dotatate radioligand therapy through the abbreviated new drug...
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
